title: The effects of combining serotonin reuptake inhibition and 5-HT7 receptor blockade on circadian rhythm regulation in rodents.
abstract: Disruption of circadian rhythms may lead to mood disorders. The present study investigated the potential therapeutic utility of combining a 5-HT7 antagonist with a selective serotonin (5-HT) reuptake inhibitor (SSRI), the standard of care in depression, on circadian rhythm regulation. In tissue explants of the suprachiasmatic nucleus (SCN) from PER2::LUC mice genetically modified to report changes in the expression of a key clock protein, the period length of PER2 bioluminescence was shortened in the presence of AS19, a 5-HT7 partial agonist. This reduction was blocked by SB269970, a selective 5-HT7 antagonist. The SSRI, escitalopram, had no effect alone on period length, but a combination with SB269970, yielded significant increases. Dosed in vivo, escitalopram had little impact on the occurrence of activity onsets in rats given access to running wheels, whether the drug was given acutely or sub-chronically. However, preceding the escitalopram treatment with a single acute dose of SB269970 produced robust phase delays, in keeping with the in vitro explant data. Taken together, these findings suggest that the combination of an SSRI and a 5-HT7 receptor antagonist has a greater impact on circadian rhythms than that observed with either agent alone, and that such a multimodal approach may be of therapeutic value in treating patients with poor clock function.
authors.affiliation: Lundbeck Research USA, 215 College Avenue, Paramus, NJ 07652, USA. westrich@fdu.edu
authors.forename: Ligia
authors.initials: L
authors.lastname: Westrich
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Sprouse
authors.forename: Connie
authors.initials: C
authors.lastname: Sánchez
mesh_terms: D000818:Animals; D002940:Circadian Rhythm / Q000187:drug effects*; D015283:Citalopram / Q000494:pharmacology; D004347:Drug Interactions; D008156:Luciferases / Q000235:genetics; D049449:Luminescence; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D056950:Period Circadian Proteins / Q000235:genetics; D010636:Phenols / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011985:Receptors, Serotonin / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology; D013493:Suprachiasmatic Nucleus / Q000187:drug effects
chemical_list: D015283:Citalopram; D008156:Luciferases; D056950:Period Circadian Proteins; D010636:Phenols; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D013449:Sulfonamides; C513311:Per2 protein, rat; C404922:SB 269970; C104425:serotonin 7 receptor